Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21995644 | 1.00 | TLR8 (0.31) | TLR8TLR7TACR1 | |
| SCHEMBL22253150 | 0.78 | TSHR (0.36) | TLR8TLR7TACR1 | |
| SCHEMBL20660395 | 0.75 | BUB1 (0.34) | — | |
| SCHEMBL31513965 | 0.75 | BUB1 (0.34) | — | |
| SCHEMBL15893898 | 0.74 | — | — | |
| SCHEMBL19338318 | 0.74 | — | — | |
| SCHEMBL18995286 | 0.74 | — | — | |
| SCHEMBL24156261 | 0.71 | HRH1 (0.32) | — | |
| SCHEMBL15148173 | 0.71 | — | — | |
| SCHEMBL15893742 | 0.70 | BACE1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3887358-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166076-A | Heterocyclic compounds for the treatment of epilepsy | 大塚制药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020111263-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | SLC6A11, SCN1A, SCN1B | TLR8 1214/4885TLR7 1957/4885TACR1 1346/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | TLR8 1214/4885TLR7 1957/4885TACR1 1346/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | TLR8 1556/4885TLR7 2002/4885TACR1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.